Pharmacokinetics of oseltamivir among pregnant and nonpregnant women

Richard H. Beigi, Kelong Han, Raman Venkataramanan, Gary D. Hankins, Shannon Clark, Mary F. Hebert, Thomas Easterling, Anne Zajicek, Zhaoxia Ren, Donald R. Mattison, Steve N. Caritis

Research output: Contribution to journalReview article

56 Scopus citations

Abstract

We sought to delineate the pharmacokinetics (PK) of oseltamivir and its active metabolite oseltamivir carboxylate during pregnancy. Physiologic changes of pregnancy, including increased renal filtration and secretion, may increase the clearance of oseltamivir carboxylate. Sixteen pregnant women taking oseltamivir for prophylaxis or treatment of suspected/proven influenza infection were enrolled. Twenty-three nonpregnant reproductive-age females served as the control group. The primary PK endpoint was area under the plasma concentration time curve for oseltamivir carboxylate. Pregnancy did not alter the PK parameters of the parent compound, oseltamivir. However, for oseltamivir carboxylate the area under the plasma concentration time curve was significantly lower (P = .007) and the apparent clearance significantly higher (P = .006) in pregnant women compared with nonpregnant women. Pregnancy produces lower systemic levels of oseltamivir carboxylate. Increasing the dose and/or dosing frequency of oseltamivir during pregnancy may be necessary to achieve comparable exposure in pregnant and nonpregnant women.

Original languageEnglish (US)
Pages (from-to)S84-S88
JournalAmerican journal of obstetrics and gynecology
Volume204
Issue number6 SUPPL.
DOIs
StatePublished - Jun 2011

Keywords

  • influenza
  • oseltamivir
  • pregnancy
  • treatment

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Pharmacokinetics of oseltamivir among pregnant and nonpregnant women'. Together they form a unique fingerprint.

Cite this